REG - Venture Life Group - Change of Accounting Reference Date

Venture LifeAnnouncement

24/09/2025 14:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250924:nRSX6794Aa&default-theme=true

RNS Number : 6794A  Venture Life Group PLC  24 September 2025

24 September 2025

 

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Change of Accounting Reference Date

 

Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, confirms that,
further to the announcement on 25 July 2025, it has changed its accounting
reference date from 31 December to 31 May to in order to better align with the
Group's revised strategy, and with the objective of reducing revenue
seasonality and managing specific operating costs more effectively.

 

Accordingly, the Company's financial calendar will be as follows:

 

·      Unaudited interim accounts for the 12-month period ending 31
December 2025, published by no later than 31 March 2026;

·      Audited accounts for the 17-month period ending 31 May 2026,
published by no later than 30 November 2026; and

·      Unaudited interim accounts for the 6-month period ending 30
November 2026, published by no later than 28 February 2027.

 

Thereafter, the Company will publish each year its final audited results for
the 12-month period ending 31 May as well as its unaudited interim results for
the six-month period ending 30 November.

 

 

For further information, please contact:

 

Venture Life Group
PLC
                +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

 

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NARFLFVVADISFIE